Melatonin protects against streptozotocin-induced diabetic cardiomyopathy through the mammalian target of rapamycin (mTOR) signaling pathway

Creative Commons License

Kandemir Y. B., Tosun V., GÜNTEKİN Ü.

ADVANCES IN CLINICAL AND EXPERIMENTAL MEDICINE, vol.28, no.9, pp.1171-1177, 2019 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 28 Issue: 9
  • Publication Date: 2019
  • Doi Number: 10.17219/acem/103799
  • Journal Name: ADVANCES IN CLINICAL AND EXPERIMENTAL MEDICINE
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.1171-1177
  • Keywords: melatonin, diabetic cardiomyopathy, mammalian target of rapamycin, NLRP3 INFLAMMASOME ACTIVATION, LEFT-VENTRICULAR MASS, HEART, METABOLISM, PRESERVATION, RECOVERY, RATS
  • Akdeniz University Affiliated: Yes

Abstract

Background. Several studies demonstrated that the overexpression of mammalian target of rapamycin (mTOR) signaling protein is associated with cardiomyopathy. However, the effect of mTOR on the heart in hyperglycemic condition is still controversial.